Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Saturday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

OGEN stock opened at $0.34 on Friday. Oragenics has a 1-year low of $0.29 and a 1-year high of $7.74. The business has a fifty day moving average price of $0.64 and a 200-day moving average price of $1.13.

Oragenics (NYSE:OGEN) last issued its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the Securities & Exchange Commission. 18.71% of the stock is currently owned by institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.